These mutations occur in approximately 24% of aCML cases and are frequently located within codons 858–871, leading to a gain-of-function effect that disrupts ubiquitination, thereby increasing SETBP1 protein levels and promoting leukemic cell proliferation [236,237]. Here, SETBP1 is linked to atypical chronic myeloid leukemia, BCR-ABL1 negative.